Geovax Labs Stock Price, News & Analysis
Company Description
GeoVax Labs, Inc. (GOVX) is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies targeting some of the world’s most serious infectious diseases and solid tumor cancers. The company is described in its public disclosures as a developer of novel vaccines for threatening infectious diseases and therapies for solid tumor cancers, positioning GeoVax within the research and development segment of biotechnology.
GeoVax states that its lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine. According to multiple company news releases, this vaccine is being evaluated in Phase 2 clinical trials in several settings: as a primary vaccine for immunocompromised patients, including those with hematologic cancers and other populations for whom authorized COVID-19 vaccines may be insufficient; as a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and as a booster in healthy individuals who previously received mRNA COVID-19 vaccines. The company has also disclosed that it was awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial comparing GEO-CM04S1 with an approved COVID-19 vaccine.
Beyond infectious disease, GeoVax highlights an oncology program centered on therapies for solid tumors. Its lead oncology program is Gedeptin®, described as a novel oncolytic solid tumor gene-directed therapy. Company news reports indicate that Gedeptin has completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers and that a Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin combined with an immune checkpoint inhibitor, is planned.
GeoVax also reports work on vaccine candidates for other infectious threats. The company has disclosed development of GEO-MVA, a vaccine candidate in development for protection against Mpox and Smallpox. According to its business updates, GEO-MVA is based on the Modified Vaccinia Ankara (MVA) platform and is being advanced with cGMP manufacturing activities, including a master seed virus and clinical batch production. In addition, the company has described research programs for vaccines against hemorrhagic fever viruses such as Ebola Zaire, Ebola Sudan, Marburg, and Lassa, as well as Zika virus, and immunotherapies for multiple solid tumors, as part of its broader pipeline.
In its public communications, GeoVax emphasizes its use of MVA-based viral vectors and virus-like particle (VLP) technologies. A recent patent-related announcement describes intellectual property around vaccinia viral vectors encoding chimeric virus-like particles and highlights an immunotherapy candidate called MVA-VLP-MUC1. The company uses its MVA-VLP vaccine platform to express abnormal, aberrantly glycosylated forms of the MUC1 tumor-associated antigen, which is associated with multiple cancers, and has reported preclinical evaluations of this candidate, including combination studies with anti-PD-1 therapy and tumor recurrence models.
GeoVax has also stated that it holds worldwide rights to its technologies and product candidates and that it maintains a portfolio of wholly owned, co-owned, and in-licensed intellectual property. In one news release, the company notes that its intellectual property estate includes more than 120 granted or pending patent applications across 24 patent families, covering its vector platforms and product candidates.
The company identifies itself as headquartered in Smyrna, Georgia, as reflected in its SEC filings and corporate contact information. GeoVax’s securities filings also indicate that it is a smaller reporting company. The company’s common stock has traded on Nasdaq under the symbol GOVX; however, a Form 25 filed by Nasdaq Stock Market LLC in 2025 indicates the removal from listing and/or registration of a class of GeoVax securities (warrants) from Nasdaq. That Form 25 specifically references GeoVax Labs, Inc. and Nasdaq Stock Market LLC and describes the class of securities as warrants. The available materials do not state that the company’s common stock has been deregistered, and there is no indication in the provided data that the operating business has ceased.
GeoVax’s SEC filings and news releases describe the company as engaged in clinical development, with multiple ongoing or planned clinical trials, and as a party to government contracts and capital markets transactions. For example, the company reports government contract revenues associated with the BARDA/Project NextGen award related to GEO-CM04S1, and it has disclosed several registered direct offerings and private placements involving common stock and warrants, with proceeds intended for working capital, research and development, manufacturing, and clinical studies.
Business focus and pipeline
According to its public descriptions, GeoVax’s business centers on:
- Next-generation COVID-19 vaccination through GEO-CM04S1, including Phase 2 trials in immunocompromised patients, CLL patients, and healthy adults, as well as a planned large Phase 2b BARDA-funded trial.
- Immuno-oncology via Gedeptin, a gene-directed oncolytic therapy for solid tumors, particularly head and neck cancers, with a completed Phase 1/2 trial and a planned Phase 2 trial in first recurrent head and neck cancer in combination with an immune checkpoint inhibitor.
- MVA-based Mpox/Smallpox vaccination through GEO-MVA, with disclosed progress in cGMP manufacturing and a stated goal of creating a U.S.-based source for a Mpox vaccine.
- Additional vaccine and immunotherapy research for pathogens such as Mpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, Lassa), Zika virus, and for multiple solid tumors, including candidates like MVA-VLP-MUC1.
The company’s disclosures repeatedly refer to its strong intellectual property portfolio and worldwide rights to its technologies and products. It also notes that its leadership team has experience in value creation across multiple life science companies, although specific individuals and roles are not detailed here to maintain evergreen content.
Regulatory and capital markets activity
GeoVax regularly files reports with the U.S. Securities and Exchange Commission (SEC), including Forms 8-K describing material events such as financings, clinical and corporate updates, and stockholder votes. The company has filed registration statements on Form S-3 and S-1 to register securities offerings and warrant share resales, and has used registered direct offerings and concurrent private placements of warrants for financing, as reflected in its 2024 and 2025 filings.
A Form 25 filed in 2025 by Nasdaq Stock Market LLC concerns the removal from listing and/or registration of a class of GeoVax warrants. Other SEC filings, including proxy materials and current reports, discuss stockholder votes on matters such as warrant-related share issuance approvals and reverse stock split authorizations. These filings indicate that GeoVax continues to operate as a public company subject to SEC reporting requirements.
Position within biotechnology
Within the biotechnology sector, GeoVax characterizes itself as a clinical-stage company, meaning its product candidates are in clinical testing rather than commercialized. Its focus on vaccines for infectious diseases and immunotherapies for solid tumors places it at the intersection of infectious disease prevention and oncology treatment. The company’s emphasis on MVA-based viral vectors, virus-like particles, and gene-directed oncolytic therapies reflects a concentration on platform technologies that can be applied across multiple disease targets, as described in its press releases and filings.